|
DISCLAIMER
Note
Regarding Forward-Looking Statements: This website
may contain forward-looking statements and it
is Pain Therapeutics’ intent that such statements
be protected by the safe harbor created thereby.
We have based these forward-looking statements
on our current expectations and projections about
future events. These forward-looking statements
involve risks and uncertainties, including, but
not limited to, the following:
| •
|
those
risks and uncertainties relating to difficulties
or delays in development, testing, regulatory
approval, production and marketing of
the our drug candidates; |
| •
|
unexpected
adverse side effects or inadequate therapeutic
efficacy of our drug candidates that could
slow or prevent product approval (including
the risk that current and past results
of clinical trials are not indicative
of future results of clinical trials); |
| •
|
the
size of the potential market for the Company’s
products; |
| •
|
the
Company’s upcoming milestones; |
| •
|
the
uncertainty of patent protection for the
Company’s intellectual property
or trade secrets; |
| •
|
potential
infringement of the intellectual property
rights or trade secrets of third parties; |
| •
|
our
ability to obtain additional financing
if necessary; and |
| •
|
those
risks and uncertainties relating to the
fact that our common stock is thinly traded. |
PTI
disclaims any intent or obligation to update these
forward-looking statements, and claims the protection
of the Safe Harbor for forward-looking statements
contained in the Private Securities Litigation
Reform Act of 1995. For further information regarding
these and other risks related to the Company's
business, investors should consult the Company's
filings with the Securities and Exchange Commission.
|
